U.S. PATENT DOCUMENTS

2007/0031844	A1	2/2007	Khvorova et al.
2007/0135370	A1	6/2007	MacLachlan et al.
2007/0281899	A1	12/2007	Bumcrot et al.
2009/0053263	A1	2/2009	Cunningham et al.
2009/0143323	A1	6/2009	Bavari et al.
2009/0149403	A1	6/2009	MacLachlan
2009/0186849	A1	7/2009	Stein et al.

FOREIGN PATENT DOCUMENTS

WO	WO 2004/090108	10/2004
WO	WO 2006/050414	5/2006
WO	WO 2007/048046	4/2007
WO	WO 2009/086558 A1	7/2009
WO	WO 2011/020023	2/2011

OTHER PUBLICATIONS

Enterlein, S., et al., "Antiviral strategies against Nipah and Ebola virus: exploring gene silencing mechanisms to identify potential antiviral targets" Antiviral Research, Elsevier Science BV., May 1, 2006, p. A38, vol. 70, No. 1.

Enterlein, S., et al., "VP35 Knockdown Inhibits Ebola Virus Amplification and Protects against Lethal Infection in Mice," Antimicrobial Agents and Chemotherapy, Mar. 2006, p. 984-993.

Geisbert T.W., et al., "Postexposure protection of guinea pigs against a lethal Ebola Virus challenge is conferred by RNA interference" Journal of Infectious Diseases, Jun. 15, 2006, pp. 1650-1657, vol. 193, No. 12.

Morris, K.V., et al., "Lentiviral-mediated delivery of siRNAs for antiviral therapy," Gene Therapy, 2006, pp. 553-558, vol. 13.

Soutschek, J., et al., Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs, Nov. 2004, Nature, vol. 432, pp. 173-178.

Warfield, K., et al., "Gene-Specific Countermeasures against Ebola Virus Based on Antisense Phosphorodiamidate Morpholino Oligomers," PLoS Pathogens, Jan. 2006, pp. 0005-0013, vol. 2, Issue 1.

PCT International Search Report and Written Opinion, PCT/US2008/058100, Apr. 14, 2009, 17 pages.

Examiner's First Report on Australian Patent Application No. 2008232891, Apr. 19, 2010, 3 pages.

Examination Report for European Patent Application No. EP 08744294.3, Jul. 21, 2010, 9 pages.

Response to Communication Pursuant to Article 94(3) EPC, filed on Nov. 29, 2010, for European Patent Application No. EP08744294.3, 33 pages.

Agrawal, S., et al., "Antisense oligonucleotides: towards clinical trials." Trends in Biotechnology. Oct. 1996, vol. 14, pp. 376-387.

Bass, B., "The short answer," Nature, May 24, 2001, pp. 428-429, vol. 411.

Elbashir, S., et al., "Analysis of gene function in somatic mammalian cells using small interfering RNAs," Methods, 2002, pp. 199-213, vol. 26.

Elbashir, S., et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in mammalian cell culture," Nature, May 24, 2001, p. 494-498, vol. 411.

Elbashir, S., et al., "Functional Anatomy of siRNAs for Mediating Efficient RNAi in *Drosophila melanogaster* Embryo Lysate", The EMBO Journal, 2001, pp. 6877-6888, vol. 20, No. 23.

Elbashir, S., et al., "RNA Interference is Mediated by 21-and 22 Nucleotide RNAs," Genes & Development, 2001, pp. 188-200, vol. 15.

Fire, A., "RNA-triggered Gene Silencing," Trends in Genetics, Sep. 1999, pp. 358-363, vol. 15, No. 9.

Fire, A., et al., "Potent and Specific Genetic Interference by Double Stranded RNA in *Caenorhabditis elegans*," Nature, Feb. 19, 1998, pp. 806-811, vol. 391.

Reynolds, et al. (2004) "Rational siRNA design for RNA interference," Nature Biotechnology, vol. 22, No. 3, pp. 326-330.

Robbins, M., et al., "Stable expression of shRNAs in human $CD34^+$ progenitor cells can avoid induction of interferon responses to siRNAs in vitro," Nature Biotechnology, May 2006, pp. 566-571, vol. 24, No. 5.

Rose, S., et al., "Functional polarity is introduced by Dicer processing of short substrate RNAs," Nucleic Acids Research, 2005, pp. 4140-4156, vol. 33, No. 13.

Tuschl, T., "Functional genomics: RNA sets the standard," Nature, Jan. 16, 2003, vol. 421, No. 6920, pp. 220-221.

Tuschl T., "RNA Interference and Small Interfering RNAs" Chembiochem, 2001, pp. 239-245, vol. 2.

Tuschl, T., et al., "Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy," Molecular Interventions, 2002, pp. 158-167, vol. 2, No. 3.

Tuschl, T., "Mammalian RNA Interference," RNAi, A Guide to Gene Silencing, Chapter 13, G.J. Hannon (ed,), 2003, pp. 265-295.

Tuschl, T., et al., "Targeted mRNA Degradation by Double-Stranded RNA in Vitro," Genes & Development, 1999, pp. 3191-3197, vol. 13.

Tuschl, T., "Expanding small RNA interference," Nature Biotechnology, May 2002, pp. 446-448, vol. 20.

Vickers, T., et al., "Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents," The Journal of Biological Chemistry, Feb. 28, 2003, pp. 7108-7118, vol. 278, No. 9.

Weil, et al (2002) "Targeting the Kinesin Eg5 to Monitor siRNA Transfection in Mammalian Cells," *Biotechniques* 33(6):1244-1248.

Zimmerman, et al. (2006) "RNAi-mediated gene silencing in non-human primates," *Nature*, vol. 441, May 4: 111-114.

Examiner's Report on Australian Patent Application No. AU 2008232891, mailed on Aug. 9, 2011, 2 pages.

Feldmann, et al., "Effective Post-Exposure Treatment of Ebola Infection," PLos Pathog, 2007.

Leung, et al., "Structure of the Ebola VP35 interferon inhibitory domain," Proc. National Academy of Science, (2009) vol. 106(2):411- 416.

Semple, et al., "Rational design of cationic lipids for siRNA delivery," National Biotechnology, Feb. 2010, pp. 172-176, vol. 28, No. 2.

PCT International Search Report and Written Opinion, PCT/US2010/045478, Feb. 9, 2011, 14 pages.

Communication pursuant to Article 94(3) EPC for European Patent Application No. EP 08744294.3, May 23, 2012, 7 pages.

Notice of Reasons for Rejection for Japanese Patent Application No. JP 2010-501154, Apr. 24, 2012, 9 pages.

Genbank Accession No. AY354458.1, "Zaire ebolavirus strain Zaire 1995, complete genome," NCBI , Feb. 2004, 21 pages, [online] [retrieved on Apr. 19, 2012] Retrieved from the internet <URL:http://www.ncbi.nlm.nih.gov/nuccore/AY354458>.

* cited by examiner